Overview

Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.

Status:
Active, not recruiting

Trial end date:
2022-03-30

Target enrollment:

Participant gender:

Summary

Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer